Journal
BLOOD
Volume 113, Issue 26, Pages 6522-6527Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-03-195966
Keywords
-
Categories
Funding
- National Institutes of Health [CA70970]
Ask authors/readers for more resources
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis. Many of the clinical manifestations of the disease result from complement-mediated intravascular hemolysis. Allogeneic bone marrow transplantation is the only curative therapy for PNH. Eculizumab, a monoclonal antibody that blocks terminal complement activation, is highly effective in reducing hemolysis, improving quality of life, and reducing the risk for thrombosis in PNH patients. Insights into the relevance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indications for treating PNH patients with bone marrow transplantation and eculizumab are explored. (Blood. 2009; 113: 6522-6527)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available